MustGrow Announces "Fireside Chat" Webcast with Bayer AG
The first Bayer milestone payment was linked to technical product development; additional payments depend on further achievements.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
MustGrow Biologics (MGROF) will host a fireside-chat webcast with Bayer on October 28, 2026, discussing their partnership and biological agriculture. The panel features MustGrow COO Colin Bletsky and Bayer's Ralf Glaubitz at 4:05pm Eastern Standard Time.
MustGrow recently received its first development milestone payment under its Bayer agreement. Additional milestone payments depend on further achievements; royalties and manufacturing sales fees depend on commercial sales commencing, if any.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate pointFirst development milestone payment received under the Bayer agreement, linked to technical product development milestones.
- Minor pointBayer license and collaboration agreement covers mustard-based biocontrol technologies for soil applications in Europe, Middle East and Africa.
Negative
- Minor point. Forward-looking: it has not happened yet and may not happen.Potential additional milestone payments depend on additional achievements.
- Minor point. Forward-looking: it has not happened yet and may not happen.Royalties and manufacturing sales fees depend on commercial sales commencing, if any.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Saskatoon, Saskatchewan--(Newsfile Corp. - October 26, 2026) - MustGrow Biologics Corp. (TSXV: MGRO) (OTCQB: MGROF) (FSE: 0C0) (the "Company" or "MustGrow") announces an upcoming webcast panel discussion with Bayer AG (BAYN) ("Bayer") featuring MustGrow's Chief Operating Officer Colin Bletsky with Ralf Glaubitz, Head of Crop Protection Product Team Biologicals at Bayer's Crop Science division.
The "fireside chat" panel discussion will be broadcasted on:
Wednesday, October 28, 2026 at 4:05pm Eastern Standard Time / 10:05pm Central European Time
Participants may register here
Or paste the following link into your browser:
https://riverside.com/webinar/registration/eyJldmVudElkIjoiNmFkYTc2MDRkZGY4MWZjN2I3OTRhZTg0Iiwic2x1ZyI6Im1hcmtldC1vbmUtc3R1ZGlvIn0=
MustGrow's Colin Bletsky and Bayer's Ralf Glaubitz will be discussing the global biological agriculture opportunity, regulatory framework, and future prospects of their partnership.
MustGrow recently announced the receipt of its first development milestone payment Bayer, part of their License and Collaboration Agreement, which covers Bayer's access to MustGrow's mustard-based biocontrol technologies covering soil applications in Europe, Middle East and Africa. This first milestone payment was linked to technical product development milestones. Going forward, potential additional milestone payments payable to MustGrow are linked to additional achievements. Upon commencement of commercial sales, if any, MustGrow will also be entitled to fees from royalties and manufacturing sales. Unless terminated earlier as provided in the Agreement, the term of the Agreement shall continue until the expiration of all intellectual property licensed to Bayer under the Agreement.
About MustGrow
MustGrow Biologics Corp. is a provider of innovative biological and regenerative agriculture solutions designed to support sustainable farming. The Company's technology is centered on harnessing the natural defense mechanisms and organic compounds found in mustard seed and formulating them into organic biofertility, biostimulant, and biocontrol products. These solutions are designed to protect soil health and the soil microbiome, support plant health, and contribute to global food security through more sustainable agricultural practices. In the United States, MustGrow's flagship biofertility product, TerraSanteTM, is registered, organically certified, and commercially sold in key agricultural states, including California. Outside of North America, MustGrow is focused on collaborating with leading global agriculture companies, such as Bayer AG in Europe, the Middle East, and Africa, to commercialize its wholly owned proprietary products and technologies. The Company is dedicated to driving shareholder value through the commercialization and expansion of its intellectual property portfolio, which includes approximately 110 issued and pending patents. MustGrow is publicly traded on the TSX Venture Exchange under the symbol MGRO and has approximately 70.4 million common shares issued and outstanding, and approximately 93.0 million shares on a fully diluted basis.
Contact Information
Corey Giasson
Director & CEO
Phone: +1-306-668-2652
info@mustgrow.ca
This release does not constitute an offer for sale of, nor a solicitation for offers to buy, any securities in the United States.
Neither the TSXV, nor their Regulation Services Provider (as that term is defined in the policies of the TSXV), nor the OTC Markets has approved the contents of this release or accepts responsibility for the adequacy or accuracy of this release.
© 2026 MustGrow Biologics Corp. All rights reserved.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/320636
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.